58 results about "Hsv infection" patented technology

Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

The invention provides modified HSV vectors that exhibit enhanced entry of cells, either through direct infection and / or lateral spread. In one aspect, HSV vectors of the present invention can directly infect cells through interaction with cell proteins other than typical mediators of HSV infection. In another aspect, the invention provides an HSV vector, which exhibits lateral spread in cells typically resistant to HSV lateral spread, such as cells lacking gD receptors. The invention further provides DNA encoding mutant forms of the HSV gB and gH glycoproteins, stocks of the inventive virus, and methods for effecting viral targeting and efficient entry of cells. The invention also pertains to the use of the inventive vectors for treating cancers.

The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and / or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.

The invention discloses a recombinant fowl adenovirus type 4 (FAdV-4) fiber2 protein as well as a preparation method and application thereof, and belongs to the technical field of gene engineering. The recombinant protein is obtained by removing 274 amino acid residues at the N end of the fowl adenovirus type 4 fiber2 protein and then recombining with the 21-55th amino acid sequence of the fowl adenovirus type 4 hexon protein; and can be used for preparing the avian adenovirus 4-type genetic engineering subunit vaccine. Aiming at the defects of poor solubility and immunogenicity of prokaryoticexpression natural fiber2 protein, the fiber2 protein coding gene is subjected to series modification, and compared with the unmodified fiber2 protein, the recombinant protein has the advantages thatthe gene coding sequence of 274 amino acid residues at the N end of the fiber2 protein is removed, and the gene coding sequences of two important antigen epitopes of the hexon protein are fused; so that the solubility and the immunogenicity are obviously improved, so that the subunit vaccine which is controllable in quality, safe and effective and can prevent highly pathogenic FAdV-4 virus infection can be prepared, and complete protection can be obtained by once immunization.

This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.

The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual.

The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.